The most commonly used noninvasive test for colorectal cancer (CRC) screening has been the guaiac fecal occult blood test (gFOBT). The fecal immunochemical test (FIT) detects CRC and colorectal polyps with higher levels of sensitivity than the gFOBT, and may be more acceptable to patients. However, the FIT has not replaced the gFOBT in many clinical settings. We analyzed data from a large healthcare system that replaced the gFOBT with the FIT to determine the effects on CRC screening.
METHODS:
We conducted a retrospective observational study of 7898 patients at the Veterans' Administration San Diego Healthcare System, 50-75 years old, who were offered stool-based CRC screening as part of primary care March 2014 through January 2015. Test orders and results were extracted from electronic health records; we performed manual reviews of colonoscopy and pathology reports for Veterans with positive results from the tests. Our primary outcome was test completion within 1 year of order; secondary outcomes were positive results and detection of advanced neoplasia by diagnostic colonoscopy. The primary analysis used an intention-to-screen approach, which included all patients with test orders; as-screened analyses were also performed.
RESULTS:
Among 7898 patients, 3236 had gFOBT and 4662 FIT orders. In the intention to screen analysis, a significantly higher proportion of subjects completed a FIT (42.6%) than a gFOBT (33.4%) (P < .001); advanced neoplasia was detected in a significantly higher proportion of subjects offered a FIT (0.79%) than a gFOBT (0.28%) (P [ .003). The numbers needed to invite to achieve 1 additional completed test and identify 1 additional patient with advanced neoplasia were 11 and 196, respectively.
CONCLUSIONS:
In a retrospective study of patients at a Veterans' administration healthcare system, replacing the gFOBT with the FIT increased the proportion of patients who completed CRC screening. Replacement of the gFOBT with the FIT should be strongly considered by all healthcare systems.
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C olorectal cancer (CRC) is the second leading cause of cancer mortality in the United States. [1] [2] [3] Screening can reduce incidence and mortality but is often underused with just 57.2%-66.6% of the eligible population up-to-date. [3] [4] [5] Furthermore, screening rates have been stagnant, with virtually no improvement from 2010-2013, per the National Health Interview Survey. 4 Screening can be done with invasive modalities (ie, colonoscopy) and noninvasive methods (ie, guaiac fecal occult blood test [gFOBT] ). Randomized trials suggest offering noninvasive options for screening may substantially impact screening rates. [6] [7] [8] Historically, the most commonly used noninvasive test for CRC screening has been gFOBT. A newer approach, the fecal immunochemical test (FIT), has shown to be more sensitive for CRC and colorectal polyps 9, 10 and may be more acceptable to patients because FIT can often be done with 1 sample (instead of 3) and does not require dietary restrictions, such as meat avoidance. [11] [12] [13] Despite evidence that FIT is a superior and more acceptable test from randomized studies, FIT has not yet replaced gFOBT in all clinical settings in the United States, although it has become the test of choice for populationbased CRC screening in many European nations. 14 We aimed to take advantage of a natural experiment in which a large healthcare system replaced gFOBT with FIT to determine impact on CRC screening.
Methods

Design and Setting
We conducted a retrospective observational study at the VA San Diego Healthcare System (VASDHS). VASDHS is one of the largest VA healthcare systems in the United States, serving 78,799 Veterans in 2014. Health care is provided through multiple primary care clinics in urban and suburban settings, and a large hospital that provides colonoscopy services. Before July 2014, when noninvasive CRC screening was offered, a 3-sample Hemoccult Sensa gFOBT test (Hemoccult Sensa, Brea, CA) was distributed at point of primary care and returned either by mail or in person. From July to August 2014, VASDHS transitioned to using a 1-sample FIT (Polymedco OC auto 80, Cortland, NY), also returned either by mail or in person. The manufacturer recommended cutoff of 100 ng of hemoglobin per 1-mL buffer signifying 20 mg of hemoglobin/ gram of stool was used as a positive FIT. Usual care followup at VASDHS for abnormal gFOBT and FIT included automated results reported to the ordering provider that may trigger an order for diagnostic colonoscopy; and active monitoring of all abnormal FIT and gFOBT results by the gastroenterology service, with case management to promote diagnostic colonoscopy completion for patients that were candidates for screening. All colonoscopies were completed at VASDHS; "fee-basis" colonoscopy was not offered during the study period.
We included Veterans age 50-75 with an order for gFOBT or FIT issued at an outpatient primary care setting from March 2014 through January 2015. For patients with multiple tests ordered over time, only the first test ordered during the study period was used as part of this analysis. Tests ordered in nonprimary care settings (eg, inpatient or emergency room) were excluded to minimize inclusion of tests done for nonscreening purposes. Test orders and results, and demographic characteristics were extracted using electronic health records, followed by manual review of colonoscopy and pathology reports for Veterans with positive tests. To search for evidence of colonoscopies performed outside VASDHS (eg, another VA site or private provider), we used an electronic health records free-text search for the term "colonoscopy" within titles and progress notes, and did not identify any reference to colonoscopies performed outside VASDHS. Colonoscopy and pathology reports were specifically reviewed to ascertain presence of any advanced neoplasia. Advanced neoplasia in this analysis included any CRC or advanced adenoma, defined as an adenoma >1 cm, villous or tubulovillous histology, and high-grade dysplasia. The VASDHS Institutional Review Board approved the study with a waiver of informed consent.
Statistical Analysis
The primary outcome was test completion within 1 year of test order; secondary outcomes were test positivity, colonoscopy completion within 1 year after having a positive test, and advanced neoplasia detection. The primary analysis used an intention-to-screen approach, considering all patients with test orders to capture impact of replacing gFOBT with FIT from the health system/population perspective. 10 As such, the intention-to-screen results help to characterize impacts on healthcare use (eg, increases in tests returned requiring laboratory processing, and positive tests requiring diagnostic colonoscopy) and health outcomes (eg, increase in advanced neoplasia detected). "As-screened" analyses were also performed. Table 1 outlines the definition of study sample for each outcome in intention-to-screen and as-screened analyses. For each outcome, proportions were computed for FIT and gFOBT separately and compared using the chisquare test. Additionally, we computed number needed to invite to achieve 1 additional screening and to detect 1 additional Veteran with advanced neoplasia for FIT vs gFOBT. Demographic characteristics were summarized using descriptive statistics and compared between FIT and gFOBT using independent 2-sample Student's t test and chi-square test. To take into account nesting of subjects within providers, and providers within location, the difference in test completion between FIT and gFOBT was assessed using generalized linear mixed effects models. Demographics (eg, age and race/ ethnicity) were included in the multivariable model as covariates. All analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC) and P < .05 was considered statistically significant for all comparisons.
Results
After applying exclusion criteria, 7898 patients with orders for gFOBT (n ¼ 3236) or FIT (n ¼ 4662) were identified during the study timeframe (the full outline of the study flow is provided in Supplementary Figure 1) . Demographic characteristics for Veterans with gFOBT vs FIT orders were similar with respect to age, gender, and race/ethnicity (Table 2) .
On intention-to-screen analyses, FIT was superior to gFOBT for test completion (42.6% for FIT vs 33.4% for gFOBT; P < .001) and advanced neoplasia detection (0.79% for FIT vs 0.28% for gFOBT; P ¼ .003) ( Table 3) . Number needed to invite for FIT over gFOBT to achieve 1 additional completed test was 11, and to detect 1 additional Veteran with advanced neoplasia was 196.
On as-screened analyses, rates of test positivity (9.3% for FIT vs 5.6% for gFOBT; P < .001) and advanced neoplasia detection (36.6% for FIT vs 19.6% for gFOBT; P ¼ .008) were higher for FIT vs gFOBT (Table 4) . CRC was diagnosed after positive FIT for 3 veterans and after positive gFOBT for 1 Veteran; small numbers precluded statistical comparison. Variation in colonoscopy completion after positive test results was observed (Table 5 ). Follow-up colonoscopy completion rates were higher for gFOBT (75.4%) vs FIT (54.6%) with P ¼ .056.
On multivariable analysis for intention-to-screen subjects adjusted for age and race/ethnicity, test type offered was significantly associated with test completion (odds ratio, 1.51; 95% confidence interval, 1.10-2.08; P ¼ .019 for FIT vs gFOBT) ( Table 6 ). We also found that older veterans (odds ratio, 1.11 for every 5-year increase; 95% confidence interval, 1.07-1.15; P < .001) and Asian ethnicity (odds ratio, 1.48 compared with whites persons; 95% confidence interval, 1.23-1.78; P < .001) were independently associated with increased likelihood of test completion.
Discussion
Taking advantage of a natural experiment within a large integrated healthcare system, we found that replacing gFOBT with FIT as the usual care outpatient noninvasive CRC screening test had a substantial impact on screening. The absolute increase in test completion percentage was 9.2% for FIT vs gFOBT, and 1.5-fold higher for FIT vs gFOBT on adjusted analyses. Because of increased completion, replacing gFOBT with FIT increased number of laboratory tests requiring processing and demand for diagnostic colonoscopy.
These results have several clinical implications. With a simple change (replacing gFOBT with FIT), health systems can markedly increase proportion of patients up-to-date with screening, and proportion of patients receiving an opportunity for early detection and prevention of CRC. As such, health systems that replace gFOBT with FIT could provide substantial benefit to their populations. Notably, FIT implementation may result in increased resource demands for laboratory processing (because of increase in tests returned) and diagnostic colonoscopy (because of higher positivity rates). For example, based on our findings, we estimate that for every 1000 tests completed there will be 42 colonoscopies required for gFOBT and 51 for FIT, a total increase in 9 colonoscopies per 1000 tests completed.
Also, resource demands for laboratory processing may differ based on type of FIT implemented. For example, the test implemented at VASDHS allows for automated batch processing, interpretation and results, whereas gFOBT required manual processing, interpretation, and results entry. In this scenario, the increased demand on laboratory resources is in the accession and storage of an increased volume of tests. Other Food and Drug Administration-approved FITs require manual processing, interpretation, and results entry. Thus, implementing a FIT with automated processing might decrease demands on laboratory personnel, whereas implementing a FIT with manual processing might increase demands.
Our results may be compared with findings from randomized comparisons of gFOBT and FIT. The 9.2% absolute increase in test completion we observed for FIT is similar in magnitude to results of a recent pooled meta-analysis by Vart et al 13 that showed completion percentages of 48.1% for FIT vs 39.2% for gFOBT among 7 pooled prospective studies comparing participation rates for the 2 tests. Population-based research studies have shown higher rates of advanced neoplasia detection associated with FIT vs gFOBT, similar to our results. [9] [10] [11] 13, 15 Similar to our study, an analysis of the impact of replacing gFOBT with FIT for a usual care mailed outreach strategy offering CRC screening at a large US integrated healthcare organization increased participation 1.3-fold. 16 Taken together, results from Lilies et al 16 and our study confirm that the benefits of choosing FIT over gFOBT observed in research studies can be realized in usual practice. In addition, these results point out the fact that screening completion rates are still suboptimal, and may be improved by additional strategies to increase patient compliance. 17 Several limitations may be considered when interpreting our results. First, unexpected significant variation in the proportion completing diagnostic colonoscopy was observed between individuals with positive FIT and those with positive gFOBT. Prior randomized trials offering gFOBT vs FIT have not reported substantial differences in rates of diagnostic colonoscopy follow-up for positive gFOBT vs FIT. 10, [18] [19] [20] [21] We speculate several potential reasons for this variation. Because gFOBT is a more cumbersome test, the population completing this test might be more likely to follow up with subsequent testing. Higher number of positive tests after transition to FIT may have strained colonoscopy capacity, leading to delays in colonoscopy scheduling. Delays in scheduling may have resulted in more loss to follow-up among FIT-positive patients. Additionally, during the study timeframe, the gastrointestinal case manager responsible for follow-up of abnormal fecal occult blood tests was replaced. Thus, time required for training may have contributed to a lower colonoscopy completion rate among positive FIT patients. Notably, even despite a lower diagnostic follow through rate, the proportions completing colonoscopy and with advanced neoplasia detected were higher among Veterans offered FIT vs gFOBT on intention-toscreen analysis. This implies that with improved case management after positive FIT, even better outcomes might be realized. A second limitation is that we cannot exclude the possibility of secular trends contributing to increases in CRC test completion. However, other than replacing FIT with gFOBT as the primary noninvasive screening option, no other system-level changes were made in provider reminders or screening processes at VASDHS. Specifically, high-definition colonoscopies were in use the entire period, no quality improvement initiatives for increasing adenoma detection were implemented, and no major changes in colonoscopist staffing occurred. Third, beyond limiting our analysis to tests done only in the outpatient setting, we were unable to confirm that all tests were done for screening (vs diagnostic) purposes; it is unclear whether this might have impacted our results in a differential manner for gFOBT vs FIT orders.
Conclusions
We found that in a large usual practice healthcare setting, replacing gFOBT with FIT for CRC screening offered as part of usual care improved screening outcomes at a system-wide level. Widespread implementation of FIT over gFOBT should be strongly considered by all healthcare systems, and may have a substantial impact on CRC detection and prevention.
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